GB0303609D0 - Novel therapeutic method and compositions - Google Patents

Novel therapeutic method and compositions

Info

Publication number
GB0303609D0
GB0303609D0 GBGB0303609.2A GB0303609A GB0303609D0 GB 0303609 D0 GB0303609 D0 GB 0303609D0 GB 0303609 A GB0303609 A GB 0303609A GB 0303609 D0 GB0303609 D0 GB 0303609D0
Authority
GB
United Kingdom
Prior art keywords
compositions
therapeutic method
novel therapeutic
novel
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0303609.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0303609.2A priority Critical patent/GB0303609D0/en
Publication of GB0303609D0 publication Critical patent/GB0303609D0/en
Priority to PCT/US2004/004329 priority patent/WO2004073622A2/en
Priority to US10/545,773 priority patent/US20060159648A1/en
Priority to JP2006503567A priority patent/JP2006517973A/ja
Priority to EP04711167A priority patent/EP1594959A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0303609.2A 2003-02-17 2003-02-17 Novel therapeutic method and compositions Ceased GB0303609D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
PCT/US2004/004329 WO2004073622A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration
US10/545,773 US20060159648A1 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration
JP2006503567A JP2006517973A (ja) 2003-02-17 2004-02-13 新規な治療方法および局所投与用組成物
EP04711167A EP1594959A4 (en) 2003-02-17 2004-02-13 THERAPEUTIC METHOD AND COMPOSITIONS FOR TOPICAL ADMINISTRATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions

Publications (1)

Publication Number Publication Date
GB0303609D0 true GB0303609D0 (en) 2003-03-19

Family

ID=9953158

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0303609.2A Ceased GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions

Country Status (4)

Country Link
EP (1) EP1594959A4 (enExample)
JP (1) JP2006517973A (enExample)
GB (1) GB0303609D0 (enExample)
WO (1) WO2004073622A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2805746B1 (en) 2009-02-16 2020-05-06 Nogra Pharma Limited Alkylamido compounds and uses thereof
WO2011084824A1 (en) * 2009-12-21 2011-07-14 Sarah Bacus Compositions and methods for increasing cellular fat and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
AU2013248397A1 (en) 2012-04-18 2014-10-02 Nogra Pharma Limited Methods of treating lactose intolerance
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
CA3037958C (en) 2017-02-22 2022-06-14 Jeffrey L. Sugarman Glitazones for topical application
SI3921299T1 (sl) 2019-02-08 2025-03-31 Nogra Pharma Limited Postopek izdelave 3-(4'-aminofenil)-2-metoksipropionske kisline in njenih analogov in vmesnih proizvodov
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2002076177A2 (en) * 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US6747048B2 (en) * 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Also Published As

Publication number Publication date
WO2004073622A2 (en) 2004-09-02
EP1594959A2 (en) 2005-11-16
JP2006517973A (ja) 2006-08-03
EP1594959A4 (en) 2006-05-03
WO2004073622A3 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
GB0411940D0 (en) Methods and compositions
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1701725A4 (en) PROCESS AND COMPOSITIONS
EP1603543A4 (en) THERAPEUTIC COMPOSITIONS
AU2003267644A8 (en) Dental compositions and methods
AU2003256805A8 (en) Compounds compositions and methods
AU2003287443A8 (en) Compositions and methods for pain reduction
IL163876A0 (en) Therapeutic methods and compositions involving isovlav-3-ene and isoflavan structures
GB0303609D0 (en) Novel therapeutic method and compositions
EP1684771A4 (en) COMPOSITION AND METHOD
GB0222945D0 (en) Therapeutic compositions
IL172294A0 (en) Methods and compositions for interferon therapy
AU2003282722A8 (en) Therapeutic compositions
EP1583557A4 (en) VACCINE COMPOSITIONS AND METHODS
GB0324523D0 (en) Compositions and methods of treatment
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0303600D0 (en) Novel therapeutic method and compositions
GB0305699D0 (en) Therapeutic compositions and methods
GB0312122D0 (en) Therapeutic method
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
GB0211831D0 (en) Therapeutic methods and compositions
GB0313059D0 (en) Compositions and method
GB0326870D0 (en) Therapeutic methods and compositions for use therein
GB0310251D0 (en) Therapeutic methods and compositions for use therein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)